The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2008Exploring LRRK2 Substrate(s) for Parkinson Disease by Protein Arrays
Objective/Rationale:
Mutations in the leucine-rich repeat kinase 2 (LRRK2) are the most common known cause of PD. A major gap in our understanding of how LRRK2 causes PD is the lack of knowledge of... -
Clinical Intervention Awards, 2008Simvastatin for the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
Objective/Rationale:
Levodopa-induced dyskinesias are caused by an increased response of dopamine receptors to dopamine in the striatum. Among other intracellular pathways, the MAP kinase signaling... -
Clinical Intervention Awards, 2008Phase II Study of Isradipine as a Disease-modifying Agent in Early Parkinson's Disease
Objective/Rationale:
Isradipine, a drug approved by the FDA for treatment of high blood pressure, has been found to be neuroprotective in pre-clinical models of parkinsonism. The objective of this... -
Therapeutics Development Initiative -- Academic Track, 2008miRNA-based Therapy for Parkinson's Disease
Objective/Rationale:
A central pathological finding associated with PD is the presence of distinctive, abnormal aggregates in brain cells typically lost in PD, termed dopamine neurons. These... -
Therapeutics Development Initiative -- Academic Track, 2008Pre-clinical characterization of 5-HT1A/1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
Objective/Rationale:
Levodopa, which is the most commonly used medication for patients with Parkinson's disease (PD), can cause, as the disease progresses, debilitating involuntary movements, so... -
Therapeutics Development Initiative -- Academic Track, 2008Novel alpha-Synuclein Isomers as Immunogens for Immunotherapy of Parkinson Diseases
Objective/Rationale:
The excessive accumulation of alpha-synuclein (a normal protein expressed in nervous system) in the brain has been shown to contribute to the pathogenesis of Parkinson disease (PD...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.